LDL PARTICLE SIZE AND PROSTATE CANCER

低密度脂蛋白颗粒大小与前列腺癌

• 批准号: 7608201
• 负责人: Brian Jay Wells
• 金额: $ 0.33万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608201
• 关键词: Adult; Age; Age-Years; Analysis of Variance; Cancer Patient; Case-Control Studies; Computer Retrieval of Information on Scientific Projects Database; Data; Diabetes Mellitus; Exclusion Criteria; Funding; Goals; Grant; Hemochromatosis; Hypertension; Individual; Institution; Lipids; Lipoproteins; Low-Density Lipoproteins; Malignant Neoplasms; Malignant neoplasm of prostate; Metastatic Prostate Cancer; Modification; Oxidative Stress; Participant; Particle Size; Patients; Pharmaceutical Preparations; Play; Population Study; Preventive; Race; Randomized Controlled Trials; Recording of previous events; Recruitment Activity; Research; Research Design; Research Personnel; Resistance; Resources; Risk Factors; Role; Sample Size; Serum; Smoking; Smoking Status; Socioeconomic Status; Source; Standards of Weights and Measures; Tail; Testing; United States National Institutes of Health; Urology; case control; design; men; oncology; particle; size

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. LONG TERM GOAL: Obtain funding for a randomized controlled trial, to test a cancer preventive agent. This study will obtain pilot data that will help achieve this goal. SPECIFIC AIMS: Smaller low density lipoprotein (LDL) molecules are less resistant to oxidative modification, which appears to increase general markers of oxidative stress in the body. Oxidative stress is hypothesized to play a key role in prostate cancer. Correlating LDL particle size with prostate cancer would be important, since medications exist that can increase LDL size. This case control study will compare LDL particle size, markers of oxidative stress, and serum lipoprotein levels in prostate cancer patients with matched controls. HYPOTHESIS: Prostate cancer patients will have significantly smaller LDL particles than age and risk factor matched controls. STUDY POPULATION: This study will target adult men between 40-80 years of age. EXCLUSION CRITERIA: Metastatic Prostate Cancer, Cancer other than prostate cancer, hemochromatosis. DESIGN: This study will consist of a case control design with control patients that will be matched on age and current smoking status. CASES: Prostate cancer cases will be generated from Dr. Klein's urology practice at the CCF. CONTROLS: Controls will be recruited through the Department of Preventive Oncology at the CCF main campus. Controls will be matched on age and current smoking status. Control patients will consist of individuals without a history of cancer. Other controls variables will include: race, socioeconomic status, hypertension, diabetes, smoking, and use of a lipid lowering medication. SAMPLE SIZE: To achieve a power of 80% at detecting an effect size of 0.5 standard deviation difference in LDL particle size between the groups with a one tailed test and and alpha of 0.05, will require a sample size of 120 participants. Patients will be recruited in 2:1 ratio of controls:cases. ANALYSIS: LDL particle size will be compared between the cases the controls using Multiple Analysis of Variance with covariates.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 长期目标：获得随机对照试验的资金，以测试癌症预防剂。 这项研究将获得有助于实现这一目标的试点数据。 具体目标：较小的低密度脂蛋白 (LDL) 分子对氧化修饰的抵抗力较差，氧化修饰似乎会增加体内氧化应激的一般标志物。 据推测，氧化应激在前列腺癌中发挥关键作用。 将 LDL 颗粒大小与前列腺癌联系起来很重要，因为存在可以增加 LDL 大小的药物。 这项病例对照研究将比较前列腺癌患者与匹配对照组的 LDL 颗粒大小、氧化应激标志物和血清脂蛋白水平。 假设：前列腺癌患者的 LDL 颗粒明显小于年龄和危险因素匹配的对照组。 研究人群：本研究将针对 40-80 岁之间的成年男性。 排除标准：转移性前列腺癌、前列腺癌以外的癌症、血色素沉着症。 设计：本研究将包括病例对照设计，对照患者的年龄和当前吸烟状况将进行匹配。 病例：前列腺癌病例将由 Klein 博士在 CCF 的泌尿外科实践产生。 控制人员：控制人员将通过 CCF 主校区的预防肿瘤学系招募。 对照将根据年龄和当前吸烟状况进行匹配。 对照患者将由没有癌症病史的个体组成。 其他控制变量包括：种族、社会经济地位、高血压、糖尿病、吸烟和降脂药物的使用。 样本大小：为了在单尾检验和 alpha 为 0.05 的情况下检测各组之间 LDL 颗粒大小 0.5 标准差差异的效应大小时达到 80% 的功效，需要 120 名参与者的样本大小。 患者将以对照：病例 2:1 的比例招募。 分析：将使用协变量的多重方差分析来比较对照病例之间的 LDL 颗粒大小。